Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative impact of the first COVID-19 lockdown on nuclear medicine in France: the CORALINE study.
Vigne J, Peyronnet D, Leenhardt J, Dubegny C, Ardisson V, Pariscoat G, Bolot C, Rauscher A, Hallouard F, Clave-Darcissac C, Clotagatide A, Odouard E, Faivre-Chauvet A, Diehl J, Houdu B, Agostini D, Morello R. Vigne J, et al. Among authors: ardisson v. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4331-4338. doi: 10.1007/s00259-021-05361-9. Epub 2021 Jun 24. Eur J Nucl Med Mol Imaging. 2021. PMID: 34169368 Free PMC article.
Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach: phantom validation and clinical preliminary results in patients with complex hepatic vascularization treated with yttrium-90-labeled microspheres.
Garin E, Lenoir L, Rolland Y, Laffont S, Pracht M, Mesbah H, Porée P, Ardisson V, Bourguet P, Clement B, Boucher E. Garin E, et al. Among authors: ardisson v. Nucl Med Commun. 2011 Dec;32(12):1245-55. doi: 10.1097/MNM.0b013e32834a716b. Nucl Med Commun. 2011. PMID: 21862941
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group. Garin E, et al. Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29. doi: 10.1016/S2468-1253(20)30290-9. Epub 2020 Nov 7. Lancet Gastroenterol Hepatol. 2021. PMID: 33166497 Free article. Clinical Trial.
18 results